LianBio

OTC: LIANY · Healthcare · Biotechnology

PublicHQ Princeton, NJ · MercerCIK 0001831283Reports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 44

v0.1 · 5/100 weight · pillars only

↑ balance-sheet leverage, Piotroski F · ↓ listing tenure, market scale

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$110.3M

Employees

163

Market cap

$12.5M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$110.3M-$110.3M2022

Operating income-$125.4M-$125.4M2022

Total assets$320.0M$320.0M2022

Liabilities$26.3M$26.3M2022

Equity$259.9M$259.9M2022

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

LianBio earned -$110.3M in FY2022 net income.

Peers · Healthcare

Femasys Inc.41D Zeo ScientifiX, Inc.43D Regional Health Properties, Inc.67B Exicure, Inc.31D

Neighbors

Mercer →

Bristol-Myers Squibb Company$48.2B85A Essential Properties Realty Trust, Inc.$561.2M69B Clearway Energy, Inc.$1.4B56C Miami International Holdings, Inc. $1.4B43D Kardigan, Inc.——UroGen Pharma Ltd.$109.8M54D

Key facts

CEOAdam Leo Stone

SectorHealthcare

IndustryBiotechnology

HeadquartersPrinceton, NJ

ExchangeOTC: LIANY

Employees163

IPO date2021-11-01

Latest filings

8-K2024-02-13 8-K2023-12-26 8-K2023-12-20 8-K2023-12-19 8-K2023-12-06 8-K2023-12-01 8-K2023-11-13 10-Q2023-11-13

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.